Zobrazeno 1 - 10
of 191
pro vyhledávání: ''
Autor:
W.S. Kim, Jin Soo Kim, T. Kim, Ho-Young Yhim, D.-H. Yang, H.-J. Shin, G.S. Park, Jinny Park, S.J. Kim, Joon Ho Moon, Youngil Koh
Publikováno v:
Annals of Oncology. 32:552-559
Background Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). Patients and methods This phase I/II st
Autor:
Kouki Miura, Shin-etsu Kamata, Chihiro Fushimi, Hideaki Takahashi, Hideaki Hirai, Takashi Matsuki, E. Hoshino, Toshitaka Nagao, Tatsuo Masubuchi, Hiroya Ojiri, Takashi Saotome, Daisuke Kawakita, Yuichiro Tada
Publikováno v:
Annals of Oncology. 29:979-984
Background There is no standard first-line chemotherapy for recurrent/metastatic (RM) or unresectable locally advanced (LA) salivary gland carcinoma (SGC). Patients and methods We conducted a single institution, open-label, single arm, phase II trial
Autor:
Punit Jain, Etsuko Aoki, Graciela M. Nogueras González, Susan O'Brien, Zeev Estrov, Farhad Ravandi, Sherry Pierce, A. Ferrajoli, Amin M. Alousi, Issa F. Khouri, William G. Wierda, Neeraj Jain, Philip A. Thompson, Hagop M. Kantarjian, Tapan M. Kadia, Jorge E. Cortes, M. Keating, E. Jabbour, Rashmi Kanagal-Shamanna, Chitra Hosing
Publikováno v:
Annals of Oncology. 28:1554-1559
Background T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. Patients and methods We reviewed the clinico-pathologic records of 119 consecutive patients with
Autor:
Kosei Matsue, Tomotaka Yoshida, Malek Faham, Tsutomu Sato, Martin Moorhead, Shigeki Ito, Victoria Carlton, Hiroyuki Takamatsu, Jianbiao Zheng, Toshiro Kurokawa, Shinji Nakao, Ryoichi Murata, Kinya Ohata, Naoki Takezako, Morio Matsumoto, Hideo Yagi, Katherine A. Kong, Kozue Yokoyama, Yasushi Terasaki, Toshihiro Miyamoto
Publikováno v:
Annals of Oncology
Background Most patients with multiple myeloma (MM) are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among these patients. Therefore, new technologies to assess deeper response are require
Autor:
Oø Bruland, Michael W. Kattan, Svein Inge Helle, Sten Nilsson, L. Xu, Daniel Heinrich, Joe M. O'Sullivan, Robert E. Coleman, M. Shan, Oliver Sartor, Scott Wilhelm, Nicholas J. Vogelzang, S. Kobina, Chris Parker
Publikováno v:
Annals of Oncology
Sartor, O, Coleman, R E, Nilsson, S, Heinrich, D, Helle, S I, O'Sullivan, J M, Vogelzang, N J, Bruland, Ø, Kobina, S, Wilhelm, S, Xu, L, Shan, M, Kattan, M W & Parker, C 2017, ' An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 ', Annals of Oncology . https://doi.org/10.1093/annonc/mdx044
Sartor, O, Coleman, R E, Nilsson, S, Heinrich, D, Helle, S I, O'Sullivan, J M, Vogelzang, N J, Bruland, Ø, Kobina, S, Wilhelm, S, Xu, L, Shan, M, Kattan, M W & Parker, C 2017, ' An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 ', Annals of Oncology . https://doi.org/10.1093/annonc/mdx044
Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not esta
Autor:
Lorenzo Marcucci, Alessandra Boccaccino, Daniele Santini, G. Aprile, Francesca Bergamo, Daniele Rossini, Rossana Intini, L. Fanchini, Angela Buonadonna, Monica Ronzoni, Gianluca Masi, Federica Morano, Evaristo Maiello, A. Falcone, Federica Marmorino, Stefano Cordio, M. Libertini, E. Fea, Emanuela Dell'Aquila, Marco Stellato
Publikováno v:
Annals of Oncology. 30:v218-v219
Background Obesity is associated with an increased risk of development and recurrence of colorectal cancer. The role of obesity in mCRC patients (pts) is still unclear, especially in those treated with triplet plus bevacizumab (bev). The aim of our s
Autor:
D.-Y. Shin, Hyoung Jin Kang, Jin Seok Kim, M. Hong, Dok Hyun Yoon, Se-Hoon Lee, Cheolwon Suh, Shinbum Kim, H.Y. Yoo, Won Seog Kim, H. Lee, Young Rok Do, H.S. Eom, Young-Hyeh Ko, W.S. Lee
Publikováno v:
Annals of Oncology. 27:712-718
Background Everolimus, an oral mTOR inhibitor, has single-agent activity against relapsed lymphomas. Thus, we carried out a phase II study of everolimus in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) as a first-
Autor:
Akira Fukutomi, Hiroyuki Isayama, Makoto Ueno, Tatsuya Ioka, J. Furuse, K. Fukuzawa, Shoji Nakamori, Haruo Iguchi, Masahiro Takeuchi, Yoshito Komatsu, Hideo Baba, Nobumasa Mizuno, Ken Shimada, Masayuki Furukawa, Masataka Ikeda, Kazuya Sugimori, Yasushi Omuro, Narikazu Boku, T. Okusaka, Ichinosuke Hyodo
Publikováno v:
Annals of Oncology
This is the first phase II trial in which adding oral leucovorin (LV) to S-1 (SL) significantly prolonged progression-free survival (PFS) when compared with S-1 monotherapy (S) in patients with gemcitabine-refractory advanced pancreatic cancer (PC).
Autor:
Ezra E.W. Cohen, Frank Worden, David N. Hayes, Heinz-Josef Lenz, Albiruni Ryan Abdul Razak, John D. Roberts, Nabil F. Saba, Kevin J. Cullen, D. Lim, Naoko Takebe, Merrill S. Kies, Jill Gilbert, Athanassios Argiris, Tawee Tanvetyanon, Theodore Karrison, Stuart J. Wong, Everett E. Vokes
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 27, iss 2
Background Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families incl
Autor:
Harry H. Yoon, Johanna C. Bendell, Philip A. Philip, D. M. Anderson, Fadi Braiteh, David Ferry, Ling Gao, Zev A. Wainberg, Edward Arrowsmith, Jonathan D. Schwartz, Yanzhi Hsu, Irfan Firdaus, Steven R. Alberts, Nancy L. Lewis, Allen Lee Cohn, Yihuan Xu
Publikováno v:
Ann Oncol
This phase II trial examined the addition of ramucirumab, a vascular endothelial growth factor receptor-2 monoclonal antibody, to mFOLFOX6 as front-line therapy for patients with advanced gastric/GEJ or esophageal adenocarcinoma. A survival benefit w